M eanwhile, the results of the global Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent (TD) alpha- or beta-thalassemia were announced showing that it achieved its primary endpoint of transfusion reduction response. Statistical significance was also achieved for all key secondary endpoints evaluating additional measures of reduction of transfusion burden compared to placebo. The results of this groundbreaking study builds upon the findings of the ENERGIZE study, highlighting the efficacy and safety of a new oral therapy for thalassemia. The full results of the study will be reported later this year.
Feat Focus Burjeel Holdings 37
Made with FlippingBook - professional solution for displaying marketing and sales documents online